Literature DB >> 25724222

[Mexican guidelines on the diagnosis and treatment of urticaria].

Désirée Larenas-Linnemann1, Miguel Alejandro Medina-Ávalos, José Antonio Ortega-Martell, Angélica María Beirana-Palencia, María Isabel Rojo-Gutiérrez, Martha Alejandra Morales-Sánchez, Héctor Solorio-Gómez, María Lourdes Alonzo-Romero Pareyón, Jorge Bernardo Vargas-Correa, Carlos Baez-Loyola, Roberto Blancas-Espinosa, Joaquín Esquer-Flores, Javier Gómez-Vera, María Graciela Guzmán-Perea, Alejandra Macías-Weinmann, César Alfonso Maldonado-García, José Darío Martínez-Villarreal, Juan José Matta-Campos, Elías Medina-Segura, Blanca Del Río-Navarro, Juan Ignacio Salgado-Gama, Héctor Stone-Aguilar, Juan José Luis Sienra-Monge, Sandra Nora González-Díaz, Enrique Mendoza-López, Mario Amaya-Guerra, Alicia Lemini-López, Andrés Blanco-Montero, María Teresa Chavarría-Jiménez, Martha Graciela Guerrero-Michaus, Albina Martínez-Pérez, Ruth Ivonne Mireya Ramírez-Segura, Gabriel Montes-Narváez, Jorge Olvera-Salinas, Ana Beatriz Rosas-Sumano.   

Abstract

BACKGROUND: Urticaria is a disease that a fifth of the population shallsuffer once in a lifetime. Recent clinical guidelines have proposed some fundamental changes in the diagnosis and treatment of urticaria, making the development of a national, multidisciplinary guideline, with wide acceptability among different professional groups -both specialists and primary health care workers-, necessary in Mexico. MATERIAL AND
METHOD: Internationally recognized tools for guidelinedevelopment were used. An interdisciplinary group of clinical experts (some of them knowledgeable in methodology of guideline development) determined the objectives and scope of the Evidence Based Clinical Practice Guideline with SCOPE. It was decided to adapt and transculturize international guidelines on the diagnosis and treatment of urticaria. With AGREE-II three high-quality guidelines (Zuberbier 2014, Sánchez-Borges 2012, Powell 2007) were selected to function as basic guidelines (BG). A set of Clinical Questions was formulated that lead to recommendations/suggestions, based on these BG, taking into account the cultural and economic background of Mexico, according to GRADE recommendation development.
RESULTS: By a formal process of discussion and voting during several working-sessions, experts and first level healthcare physicians determined the wording of the final guideline, taking particularly care of developing a document, adjusted to the reality, values and preferences of the Mexican patients. The use of oral second generation, non-sedating antihistamines as first line treatment is emphasized.
CONCLUSION: This document is an Evidence Based Clinical Practice Guideline for the diagnosis and treatment of acute and chronic urticaria, based on three, high quality, international guidelines. It was developed by a multidisciplinary group. Tables and algorithms make the guideline user-friendly for both, first line health care physicians and specialists.

Entities:  

Keywords:  Angioedema; Antihistamine; Chronic urticaria; Clinical practice guideline; Corticosteroid; Cyclosporin; Omalizumab; Urticaria; Wheals

Year:  2014        PMID: 25724222

Source DB:  PubMed          Journal:  Rev Alerg Mex        ISSN: 0002-5151


  2 in total

1.  Why a registry of Chronic Urticaria (CUR) is needed.

Authors:  R M Gómez; E Jares; G W Canonica; I Baiardini; G Passalacqua; M Sánchez Borges; A P Kaplan; Carlos E Baena-Cagnani
Journal:  World Allergy Organ J       Date:  2017-05-16       Impact factor: 4.084

Review 2.  Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group.

Authors:  Désirée Larenas-Linnemann; Jorge Luna-Pech; Elsy M Navarrete-Rodríguez; Noel Rodríguez-Pérez; Alfredo Arias-Cruz; María Virginia Blandón-Vijil; Blanca E Del Rio-Navarro; Alan Estrada-Cardona; Ernesto Onuma-Takane; Cesar Fireth Pozo-Beltrán; Adriana María Valencia-Herrera; Francisco Ignacio Ortiz-Aldana; Mirna Eréndira Toledo-Bahena
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-25       Impact factor: 4.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.